SEC Filing | Aligos Therapeutics

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

2,429,895 shares of common stock(1)

Shared Voting Power

0

Sole Dispositive Power

2,429,895 shares of common stock(1)

Shared Dispositive Power

0

View:

Download DOC

Download PDF

Download XLS

SC 13D

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

TO RULE 13d-2(a)

(Amendment No. )*

Aligos Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

01626L 10 5

(CUSIP Number)

Versant Venture Capital VI, L.P.

Robin L. Praeger

One Sansome Street, Suite 3630

San Francisco, CA 94104

415-801-8100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

October 20, 2020

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Venture Capital VI, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

These shares are held by Versant VI (as defined in Item 2(a) below). Versant Ventures VI GP-GP (as defined in Item 2(a) below) is the general partner of Versant Ventures VI GP (as defined in Item 2(a) below), which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting and dispositive power with respect to the shares held by Versant VI.

(2)

Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Securities and Exchange Commission (“Commission”) on October 19, 2020.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Ventures VI GP, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

These shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting and dispositive power with respect to the shares held by Versant VI.

(2)	Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Commission on October 19, 2020.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Ventures VI GP-GP, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Commission on October 19, 2020.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Vantage I, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

These shares are held by Versant Vantage I (as defined in item 2(a) below). Versant Vantage I GP-GP (as defined in item 2(a) below) is the general partner of Versant Vantage I GP (as defined in item 2(a) below), which is the general partner of Versant Vantage I. Versant Vantage I GP-GP and Versant Vantage I GP may be deemed to share voting and dispositive power with respect to the shares held by Versant Vantage I.

(2)	Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Commission on October 19, 2020.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Vantage I GP, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

These shares are held by Versant Vantage I. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP, which is the general partner of Versant Vantage I. Versant Vantage I GP-GP and Versant Vantage I GP may be deemed to share voting and dispositive power with respect to the shares held by Versant Vantage I.

(2)	Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Commission on October 19, 2020.


CUSIP No. 01626L 10 5		13D


1.		Name of Reporting Persons Versant Vantage I GP-GP, LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

(1)

(2)	Based upon 33,797,848 shares of the Issuer’s Common Stock outstanding after the Issuer’s initial public offering, assuming no exercise of the underwriters’ over-allotment option, as reported in the Issuer’s prospectus (Form 424(b)(4)) filed with the Commission on October 19, 2020.


CUSIP No. 01626L 10 5		13D

Item 1. Security and Issuer

This joint statement on Schedule 13D (this “Statement”) is filed with respect to the common stock, par value $0.0001 per share (“Common Stock”), of Aligos Therapeutics, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is One Corporate Drive, 2^nd Floor, South San Francisco, California 94080.

Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

Item 2. Identity and Background

(a) This Statement is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Vantage I, L.P. (“Versant Vantage I”), Versant Ventures VI GP, L.P. (“Versant Ventures VI GP”), Versant Ventures VI GP-GP, LLC (“Versant Ventures VI GP-GP”), Versant Vantage I GP, L.P. (“Versant Vantage I GP”), and Versant Vantage I GP-GP, LLC (“Versant Vantage I GP-GP” and together with Versant VI, Versant Vantage I, Versant Ventures VI GP, Versant Ventures VI GP-GP and Versant Vantage I GP, collectively, the “Reporting Persons”). Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting and dispositive power with respect to the shares held by Versant VI. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP, which is the general partner of Versant Vantage I. Versant Vantage I GP, Versant Vantage I GP-GP may be deemed to share voting and dispositive power with respect to the shares held by Versant Vantage I. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Amendment except to the extent of such Reporting Person’s pecuniary interest therein.

(b) The business address for each of the Reporting Persons is:

c/o Versant Ventures

One Sansome Street, Suite 3630

San Francisco, CA 94104

(c) Each of Versant VI and Versant Vantage I are venture capital investment entities and each of Versant Ventures VI GP, Versant Ventures VI GP-GP, Versant Vantage I GP and Versant Vantage I GP-GP are the general partners of the venture capital investment entities.

(d) During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)

Versant VI – formed under the laws of the state of Delaware

Versant Vantage I – Formed under the laws of the state of Delaware

Versant Vantage I GP – formed under the laws of the state of Delaware

Versant Vantage I GP-GP – formed under the laws of the state of Delaware

Versant Ventures VI GP – formed under the laws of the state of Delaware

Versant Ventures VI GP-GP – formed under the laws of the state of Delaware

Item 3. Source and Amount of Funds or Other Consideration.

In August and September 2018, Versant VI purchased 2,145,991 shares of the Issuer’s Series A Convertible Preferred Stock for a purchase price of $9.32 per share and an aggregate purchase price of $20,000,000.

In December 2019, Versant VI purchased 198,839 shares of the Issuer’s Series B Convertible Preferred Stock for a purchase price of $10.1869 per share and an aggregate purchase price of $2,025,560 and Versant Vantage I purchased 463,959 shares of the Issuer’s Series B Convertible Preferred Stock for a purchase price of $10.1869 per share and an aggregate purchase price of $4,726,307.

In October 2020, Versant VI purchased 85,065 shares of the Issuer’s Series B-2 Convertible Preferred Stock for a purchase price of $11.20563 per share and an aggregate purchase price of $953,209 and Versant Vantage I purchased 198,485 shares of the Issuer’s Series B-2 Convertible Preferred Stock for a purchase price of $11.20563 per share and an aggregate purchase price of $2,224,154.

On October 20, 2020, effective upon the closing of the of the Issuer’s initial public offering, the Issuer’s Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series B-2 Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis for no consideration (the “Conversion”). Following the Conversion, Versant VI directly held an aggregate of 2,429,895 shares of Common Stock and Versant Vantage I directly held an aggregate of 662,444 shares of Common Stock.

In addition, on October 20, 2020, in connection with the Issuer’s initial public offering, Versant Vantage I purchased an additional 200,000 shares of Common Stock for a purchase price of $15.00 per share and an aggregate purchase price of $3,000,000 (the “IPO Purchase”). Following the Conversion and the IPO Purchase, Versant Vantage I directly held an aggregate of 862,444 shares of the Issuer’s Common Stock.

All shares of the capital stock of the Issuer covered by this Statement were originally acquired by Versant VI, and Versant Vantage I using investment funds provided to each of Versant VI and Versant Vantage I by their respective limited and general partner investors. Unless noted above, no part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.

Item 4. Purpose of Transaction

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional shares of Common Stock or other securities of the Issuer, dispose of some or all of the shares of Common Stock or other securities of the Issuer that it may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing.

The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s stock in particular, as well as other developments.

Item 5. Interest in Securities of the Issuer

(a) and (b) See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person and Item 2 above.

(c) Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer’s securities within the past 60 days.

(d) Under certain circumstances set forth in the respective limited partnership agreements of each of Versant VI, and Versant Vantage I (the “Funds”), the respective limited and general partners of the Funds may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

In connection with its purchase of shares of the Issuer’s Series B-2 Convertible Preferred Stock, Versant VI, Versant Vantage I and certain of the Issuer’s other investors entered into an Amended and Restated Investors’ Rights Agreement, dated October 9, 2020, with the Issuer (the “Rights Agreement”). After the closing of the Issuer’s initial public offering, the stockholders party thereto are entitled to certain registration rights, including the right to demand that that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Issuer’s Registration Statement on Form S-1 (File No. 333-249077) declared effective by the Commission on October 15, 2020 (the “Registration Statement”), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

In connection with the Issuer’s initial public offering, each of Versant VI and Versant Vantage I have entered into lock-up agreements, pursuant to which Versant VI and Versant Vantage I have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer’s securities held by each of Versant VI and Versant Vantage I for 180 days following the date of the underwriting agreement for the Offering. The terms and provisions of such lock-up agreements are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.

Thomas Woiwode, Ph.D. (“Dr. Woiwode”), who is a Managing Director of Versant Ventures, is also a member of the board of directors of the Issuer. In his capacity as a member of the board of directors of the Issuer, Dr. Woiwode may be entitled to receive stock options or other equity awards pursuant to the Company’s 2020 Incentive Award Plan, attached hereto as Exhibit 4.

The Issuer has entered into an indemnification agreement with each of its directors and executive officers, including Dr. Woiwode. The indemnification agreement requires the Issuer, among other things, to indemnify Dr. Woiwode for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by Dr. Woiwode in any action or proceeding arising out of his service as a director. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the indemnification agreement, which is filed as Exhibit 5 to this Statement and is incorporated herein by reference.

Item 7. Material to be Filed as Exhibits


Exhibit Number		Description

Exhibit 1		Joint Filing Agreement

Exhibit 2		Amended and Restated Investors’ Rights Agreement, dated as of October 9, 2020 (filed as Exhibit 10.4 to the Issuer’s Registration Statement on Form S-1/A as filed with the Commission on October 9, 2020 (SEC File No. 333-249077) and incorporated herein by reference).

Exhibit 3		Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (included as Exhibit D to the form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1/A as filed with the Commission on October 9, 2020 (SEC File No. 333-249077) and incorporated herein by reference).

Exhibit 4		2020 Incentive Award Plan and associated forms (filed as Exhibits 10.6(A)-(D) to the Issuer’s Registration Statement on Form S-1/A as filed with the Commission on October 9, 2020 (SEC File No. 333-249077) and incorporated herein by reference).

Exhibit 5		Form of Indemnification Agreement by and between the Issuer and its directors and officers (filed as Exhibit 10.12 to the Issuer’s Registration Statement on Form S-1/A as filed with the Commission on October 9, 2020 (SEC File No. 333-249077) and incorporated herein by reference).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


October 30, 2020

Versant Venture Capital VI, L.P.
By:		Versant Ventures VI GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP, L.P.
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP-GP, LLC

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I, L.P.
By:		Versant Vantage I GP, L.P.
Its:		General Partner
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I GP, L.P.
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I GP-GP, LLC

By:		/s/ Robin L. Praeger, Managing Director

EX-99.1

Exhibit 1

Joint Filing Agreement

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Aligos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.


October 30, 2020

Versant Venture Capital VI, L.P.
By:		Versant Ventures VI GP, L.P.
Its:		General Partner
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP, L.P.
By:		Versant Ventures VI GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP-GP, LLC

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I, L.P.
By:		Versant Vantage I GP, L.P.
Its:		General Partner
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I GP, L.P.
By:		Versant Vantage I GP-GP, LLC
Its:		General Partner

By:		/s/ Robin L. Praeger, Managing Director

Versant Vantage I GP-GP, LLC

By:		/s/ Robin L. Praeger, Managing Director